Key result
Novel FLNC variants are linked to ~3% of pediatric cardiomyopathy cases.
Observational (n=58)
No
Novel FLNC missense variants in pediatric cardiomyopathy can disrupt normal splicing, highlighting the importance of evaluating splicing effects to guide early detection and intervention.
May inform FLNC inclusion in pediatric cardiomyopathy panels; hypothesis-generating for splicing effects, requiring larger validation before practice change.
BACKGROUND: FLNC gene variants have predominantly been reported in adult populations with cardiomyopathies, and early-onset cases are less common. The genotype-phenotype relationship indicates that dilated cardiomyopathy (DCM) is often associated with FLNC truncating variants. METHODS: We conducted a comprehensive genetic analysis using next generation sequencing (NGS) to identify FLNC variants in patients with cardiovascular conditions. Detailed phenotypic and variant analyses were performed to characterize the clinical features and genetic alterations. Minigene assays and structural modeling were used to investigate the pathogenicity caused by the identified variants. RESULTS: In a cohort of 58 patients, novel heterozygous FLNC variants, c.3962A > T (p.Glu1321Val) and c.7543C > T (p.Leu2515Phe), were identified in patients presenting with dilated and mixed restrictive/hypertrophic cardiomyopathies, respectively. The c.3962A > T variant disrupted normal splicing, as demonstrated through the splicing prediction tool and minigene studies, further emphasizing its pathogenic potential. CONCLUSION: For missense variants of FLNC in patients with DCM, the splicing effect of the variant should be carefully checked. Early detection and intervention are crucial given the high risk of sudden cardiac death and severe cardiac complications.
No takes yet. Share an insight, caveat, or question.
Dong et al. (2024) conducted an observational in Pediatric cardiomyopathy, arrhythmias, and myocarditis (n=58). FLNC variants vs. Patients without FLNC variants was evaluated on Prevalence of disease-related FLNC variants. Novel heterozygous FLNC variants were identified in 3.4% (2 of 58) of pediatric patients, presenting with dilated and mixed restrictive/hypertrophic cardiomyopathies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: